Pathogenesis and Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ABSTRACT

Once thought to be a mere nuisance, exacerbations are now recognized as a major contributor to the morbidity and mortality associated with chronic obstructive pulmonary disease. This recognition has led to research using new investigative tools that has substantially enhanced our understanding of the pathogenesis of exacerbations. Several overlapping etiologies can precipitate the symptom complex of an exacerbation. Treatment of exacerbations requires the use of several therapeutic modalities with the goal of restoring the patient to baseline. Results of recent clinical trials and observational studies have allowed a refinement of the approach to treatment of exacerbations. These include a rational, stratified approach to the use of antibiotics and several trials substantiating the use of systemic corticosteroids. Relapse or failure rates of 20 to 33% have been described in the treatment of acute exacerbation, with these treatment failures contributing substantially to the costs associated with exacerbations. Improved treatment based on enhanced understanding and good clinical evidence should lead to better outcomes in this common clinical entity.

KEYWORDS

Chronic obstructive pulmonary disease - exacerbation - pathogenesis - antibiotics

REFERENCES

• 1 Mapel D W, Hurley J S, Frost F J, Petersen H V, Picchi M A, Coultas D B. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization.  Arch Intern Med. 2000;  160 2653-2658
• 2 Fabbri L M, Hurd S S. Global strategy for the diagnosis, management and prevention of COPD: 2003 update.  Eur Respir J. 2003;  22 1-2
• 3 Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations.  Chest. 2000;  117(5 suppl 2) 398S-401S
• 4 Sethi S, Evans N, Grant B JB, Murphy T F. Acquisition of a new bacterial strain and occurrence of exacerbations of chronic obstructive pulmonary disease.  N Engl J Med. 2002;  347 465-471
• 5 Saetta M, Turato G, Maestrelli P, Mapp C E, Fabbri L M. Cellular and structural bases of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  163 1304-1309
• 6 White A J, Gompertz S, Stockley R A. Chronic obstructive pulmonary disease, VI: The aetiology of exacerbations of chronic obstructive pulmonary disease.  Thorax. 2003;  58 73-80
• 7 Sethi S. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease.  Curr Opin Infect Dis. 2004;  17 113-119
• 8 Sethi S, Muscarella K, Evans N, Klingman K L, Grant B JB, Murphy T F. Airway inflammation and etiology of acute exacerbations of chronic bronchitis.  Chest. 2000;  118 1557-1565
• 9 Gompertz S, O'Brien C, Bayley D L, Hill S L, Stockley R A. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis.  Eur Respir J. 2001;  17 1112-1119
• 10 Zhu J, Qiu Y S, Majumdar S et al.. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants.  Am J Respir Crit Care Med. 2001;  164 109-116
• 11 Balbi B, Bason C, Balleari E et al.. Increased bronchoalveolar grnulocytes and granulocyte-macrophage colony-stimulating factor during exacerbations of chronic bronchitis.  Eur Respir J. 1997;  10 846-850
• 12 Saetta M, Di Stefano A, Maestrelli P et al.. Airway eosinophilia in chronic bronchitis during exacerbations.  Am J Respir Crit Care Med. 1994;  150(6 Pt 1) 1646-1652
• 13 Stockley R A. The role of proteinases in the pathogenesis of chronic bronchits.  Am J Respir Crit Care Med. 1994;  150 S109-S113
• 14 Wouters E F. Chronic obstructive pulmonary disease, V: Systemic effects of COPD.  Thorax. 2002;  57 1067-1070
• 14a Saetta M, Di Stefano A, Maestrelli J P et al.. Airway eosinophilia in chronic bronchitis during exacerbations.  Am J Respir Crit Care Med. 1994;  150 1646-1652
• 14b Crooks S W, Bayley D L, Hill S L, Stockley R A. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4.  Eur Respir J. 2000;  15 274-280
• 14c Biernacki W A, Kharitonov S A, Barnes P J. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD.  Thorax. 2003;  58 294-298
• 14d Bhowmik A, Seemungal T A, Sapsford R J, Wedzicha J A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.  Thorax. 2000;  55 114-120
• 14e Stockley R A, O'Brien C, Pye A, Hill S L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.  Chest. 2000;  117 1638-1645
• 14f Agusti A G, Villaverde J M, Togores B, Bosch M. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease.  Eur Respir J. 1999;  14 523-528
• 14g Roland M, Bhowmik A, Sapsford R J et al.. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease.  Thorax. 2001;  56 30-35
• 15 Wedzicha J A, Seemungal T A, MacCallum P K et al.. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels.  Thromb Haemost. 2000;  84 210-215
• 16 Dev D, Wallace E, Sankaran R et al.. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease.  Respir Med. 1998;  92 664-667
• 17 Ohtoshi T, Takizawa H, Okazaki H et al.. Diesel exhaust particles stimulate human airway epithelial cells to produce cytokines relevant to airway inflammation in vitro.  J Allergy Clin Immunol. 1998;  101 778-785
• 18 Devalia J L, Rusznak C, Herdman M J, Trigg C J, Tarraf H, Davies R J. Effect of nitrogen dioxide and sulphur dioxide on airway response of mild asthmatic patients to allergen inhalation.  Lancet. 1994;  344 1668-1671
• 19 Rudell B, Blomberg A, Helleday R. Bronchoalveolar inflammation after exposure to diesel exhaust: comparison between unfiltered and particle trap filtered exhaust.  Occup Environ Med. 1999;  56 527-534
• 20 Garcia-Aymerich J, Tobias A, Anto J M, Sunyer J. Air pollution and mortality in a cohort of patients with chronic obstructive pulmonary disease: a time series analysis.  J Epidemiol Community Health. 2000;  54 73-74
• 21 Sunyer J, Saez M, Murillo C, Castellsague J, Martinez F, Anto J M. Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study.  Am J Epidemiol. 1993;  137 701-705
• 22 Sunyer J, Schwartz J, Tobias A, Macfarlane D, Garcia J, Anto J M. Patients with chronic obstructive pulmonary disease are at increased risk of death associated with urban particle air pollution: a case-crossover analysis.  Am J Epidemiol. 2000;  151 50-56
• 23 Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis.  Chest. 2000;  117 380S-385S
• 24 Hirschmann J V. Do bacteria cause exacerbations of COPD?.  Chest. 2000;  118 193-203
• 25 Murphy T F, Sethi S, Niederman M S. The role of bacteria in exacerbations of COPD: a constructive view.  Chest. 2000;  118 204-209
• 26 Sethi S, Murphy T F. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.  Clin Microbiol Rev. 2001;  14 336-363
• 27 Chastre J, Fagon J-Y, Bornet-Lesco M et al.. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia.  Am J Respir Crit Care Med. 1995;  152 231-240
• 28 Monso E, Ruiz J, Rosell A et al.. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush.  Am J Respir Crit Care Med. 1995;  152 1316-1320
• 29 Fagon J-Y, Chastre J, Trouillet J-L et al.. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis.  Am Rev Respir Dis. 1990;  142 1004-1008
• 30 Soler N, Torres A, Ewig S et al.. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.  Am J Respir Crit Care Med. 1998;  157 1498-1505
• 31 Pela R, Marchesani F, Agostinelli C et al.. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation.  Monaldi Arch Chest Dis. 1998;  53 262-267
• 32 Bandi V, Apicella M A, Mason E et al.. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis.  Am J Respir Crit Care Med. 2001;  164 2114-2119
• 33 Gump D W, Phillips C A, Forsyth B R, McIntosh F K, Lamborn K R, Stouch W H. Role of infection in chronic bronchitis.  Am Rev Respir Dis. 1976;  113 465-473
• 34 McHardy V U, Inglis J M, Calder M A, Crofton J W. A study of infective and other factors in exacerbations of chronic bronchitis.  Br J Dis Chest. 1980;  74 228-238
• 35 Gog J R, Grenfell B T. Dynamics and selection of many-strain pathogens.  Proc Natl Acad Sci USA. 2002;  99 17209-17214
• 36 Sethi S, Wrona C, Grant B, Murphy T. Strain‐specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2004;  169 448-453
• 37 Bakri F, Brauer A L, Sethi S, Murphy T F. Systemic and mucosal antibody response to Moraxella catarrhalis following exacerbations of chronic obstructive pulmonary disease.  J Infect Dis. 2002;  185 632-640
• 38 Abe Y, Murphy T F, Sethi S et al.. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2002;  165 967-971
• 39 Aaron S D, Angel J B, Lunau M et al.. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  163 349-355
• 40 White A J, Gompertz S, Bayley D L et al.. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis.  Thorax. 2003;  58 680-685
• 41 Rohde G, Wiethege A, Borg I et al.. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study.  Thorax. 2003;  58 37-42
• 42 Tan W C, Xiang X, Qiu D, Ng T P, Lam S F, Hegele R G. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease.  Am J Med. 2003;  115 272-277
• 43 Seemungal T A, Harper-Owen R, Bhowmik A, Jeffries D J, Wedzicha J A. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease.  Eur Respir J. 2000;  16 677-683
• 44 Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman M G. Pneumonic vs nonpneumonic acute exacerbations of COPD.  Chest. 2002;  122 1264-1270
• 45 von Hertzen L, Alakarppa H, Koskinen R et al.. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease.  Epidemiol Infect. 1997;  118 155-164
• 46 Blasi F, Damato S, Cosentini R et al.. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment.  Thorax. 2002;  57 672-676
• 47 Lieberman D, Lieberman D, Ben-Yaakov M et al.. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.  Diagn Microbiol Infect Dis. 2002;  44 1-6
• 48 Mogulkoc N, Karakurt S, Isalska B et al.. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection.  Am J Respir Crit Care Med. 1999;  160 349-353
• 49 Miyashita N, Niki Y, Nakajima M, Kawane H, Matsushima T. Chlamydia pneumoniae infections in patients with diffuse panbronchiolitis and COPD.  Chest. 1998;  114 969-971
• 50 Karnak D, Beng-sun S, Beder S, Kayacan O. Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD).  Respir Med. 2001;  95 811-816
• 51 Hahn D L, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association.  Arterioscler Thromb. 1992;  12 945-947
• 52 Beaty C D, Grayston J T, Wang S P, Kuo C C, Reto C S, Martin T R. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1991;  144 1408-1410
• 53 Blasi F, Legnani D, Lombardo V M et al.. Chlamydia pneumoniae infection in acute exacerbations of COPD.  Eur Respir J. 1993;  6 19-22
• 54 Smith C B, Golden C, Kanner R, Renzetti Jr A D. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases.  Am Rev Respir Dis. 1980;  121 225-232
• 55 Sethi S. Acute exacerbations of COPD: a “multipronged” approach.  J Respir Dis. 2002;  23 217-255
• 56 Bach P B, Brown C, Gelfand S E, McCrory D C. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence.  Ann Intern Med. 2001;  134 600-620
• 57 Balter M S, La Forge J, Low D E, Mandell L, Grossman R F. Canadian guidelines for the management of acute exacerbations of chronic bronchitis.  Can Respir J. 2003;  10(Suppl B) 3B-32B
• 58 Murphy T F, Sethi S. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient.  Drugs Aging. 2002;  19 761-775
• 59 Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis.  JAMA. 1995;  273 957-996
• 60 Sachs A PE, Koeter G H, Groenier K H, van der Waaij D, Schiphuis J, Jong B M. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice.  Thorax. 1995;  50 758-763
• 61 Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once-daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.  Lancet. 2001;  358 2020-2025
• 62 Allegra L, Blasi F, de Bernardi B, Cosentini R, Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a reevaluation of previously published data of a placebo-controlled randomized study.  Pulm Pharmacol Ther. 2001;  14 149-155
• 63 Anthonisen N R, Manfreda J, Warren C PW, Hershfield E S, Harding G KM, Nelson N A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.  Ann Intern Med. 1987;  106 196-204
• 64 Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?.  Proc Am Thorac Soc.. 2004;  1 109-114
• 65 Wilson R, Schentag J J, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.  Clin Ther. 2002;  24 639-652
• 66 Spencer S, Jones P W. Time course of recovery of health status following an infective exacerbation of chronic bronchitis.  Thorax. 2003;  58 589-593
• 67 Wilson R, Allegra L, Huchon G et al.. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.  Chest. 2004;  125 953-964
• 68 Ball P, Harris J M, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis.  Q J Med. 1995;  88 61-68
• 69 Dewan N A, Rafique S, Kanwar B et al.. Acute exacerbation of COPD: factors associated with poor treatment outcome.  Chest. 2000;  117 662-671
• 70 Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group.  Eur Respir J. 2001;  17 928-933
• 71 Groenewegen K H, Schols A M, Wouters E F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.  Chest. 2003;  124 459-467
• 72 Adams S G, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.  Chest. 2000;  117 1345-1352